Abstract 3475: RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models
Menard, Marie J., Chow, Christopher, Chen, Kevin, Blaj, Cristina, Shifrin, Nataliya Tovbis, Courtney, Haley, Nasholm, Nicole M., Pham, Anna, Kumamoto, Alice, Ganesh, Swetha, Evans, James W., Lawrence, Lindsey, Vonmelchert, Brian, Kwok-Parkhill, Amy C., Jiang, Jingjing, Knox, John E., Smith, Jacqueline, Quintana, Elsa
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article